Correlates and Responsiveness to Change of Measures of Skin and Musculoskeletal Disease in Early Diffuse Systemic Sclerosis

Arthritis Care and Research

Volumn 66, Issue 11, 2014, Pages 1731-1739

  Wiese, Alexandra B ^a   Berrocal, Veronica J ^a   Furst, Daniel E ^b   Seibold, James R ^c   Merkel, Peter A ^d   Mayes, Maureen D ^e   Khanna, Dinesh ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Scleroderma Research Consultants   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE;

ADULT; ARTICLE; COHORT ANALYSIS; CORRELATION ANALYSIS; CREATINE KINASE BLOOD LEVEL; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; DISEASE DURATION; DUROMETER SCORE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MODIFIED RODNAN SKIN SCORE; OBSERVATIONAL STUDY; PHYSICAL EXAMINATION; QUALITY OF LIFE ASSESSMENT; SHORT FORM 36; SKIN DISEASE ASSESSMENT; SYSTEMIC SCLEROSIS; VISUAL ANALOG SCALE;

EID: 84999989137     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22339     Document Type: Article

References (33)

1. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581–90.
2. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202–5.
3. Mura G, Bhat KM, Pisano A, Licci G, Carta M. Psychiatric symptoms and quality of life in systemic sclerosis. Clin Pract Epidemiol Ment Health 2012;8:30–5.
4. Danieli E, Airo P, Bettoni L, Cinquini M, Antonioli CM, Cavazzana I, et al. Health-related quality of life measured by the Short-Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol 2005;24:48–54.
5. Del Rosso A, Boldrini M, D'Agostino D, Placidi GP, Scarpato A, Pignone A, et al. Health-related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers. Arthritis Rheum 2004;51:475–81.
6. Kallen MA, Mayes MD, Kriseman YL, de Achaval SB, Cox VL, Suarez-Almazor ME. The symptom burden index: development and initial findings from use with patients with systemic sclerosis. J Rheumatol 2010;37:1692–8.
7. De Achaval S, Kallen MA, Mayes MD, Lopez-Olivo MA, Suarez-Almazor ME. Use of the patient-generated index in systemic sclerosis to assess patient-centered outcomes. J Rheumatol 2013;40:1337–43.
8. Bassel M, Hudson M, Taillefer SS, Schieir O, Baron M, Thombs BD. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology (Oxford) 2011;50:762–7.
9. Van Lankveld WG, Vonk MC, Teunissen H, van der Hoogen FH. Appearance self-esteem in systemic sclerosis: subjective experience of skin deformity and its relationship with physician-assessed skin involvement, disease status and psychological variables. Rheumatology (Oxford) 2007;46:872–6.
10. Suarez-Almazor ME, Kallen MA, Roundtree AK, Mayes M. Disease and symptom burden in systemic sclerosis: a patient perspective. J Rheumatol 2007;34:1718–26.
11. Khanna D, Distler O, Avouac J, Behrens F, Clements PJ, Denton C, et al. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). J Rheumatol 2009;36:2356–61.
12. Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008;67:703–9.
13. Clements PJ, Lachenbruch P, Siebold JR, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281–5.
14. Khanna D, Merkel PA. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007;9:151–7.
15. Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000;43:2445–54.
16. Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, et al. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum 2009;60:2490–8.
17. Merkel PA, Silliman NP, Denton CP, Furst DE, Khanna D, Emery P, et al, for the CAT-192 Research Group and the Scleroderma Clinical Trials Consortium.Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis Rheum 2008;59:699–705.
18. Kissin EY, Schiller AM, Gelbard RB, Anderson JJ, Falanga V, Simms RW, et al. Durometry for the assessment of skin disease in systemic sclerosis. Arthritis Rheum 2006;55:603–9.
19. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.
20. Cole JC, Khanna D, Clements PJ, Seibold JR, Tashkin DP, Paulus HE, et al. Single-factor scoring validation for the Health Assessment Questionnaire-disability index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. Qual Life Res 2006;15:1383–94.
21. Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire disability index in a systemic sclerosis clinical trial. J Rheumatol 2005;32:832–40.
22. Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. The disability index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum 2001;44:653–61.
23. Khanna PP, Furst DE, Clements PJ, Maranian P, Indulkar L, Khanna D. Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. Rheumatology (Oxford) 2010;49:955–9.
24. Cohen J.Statistical power analysis for the behavioral sciences. 2nd ed.Hillsdale (NJ):Erlbaum; 1988.
25. Cohen J. A power primer. Psychol Bull 1992;112:155–9.
26. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis [review].Clin Exp Rheumatol 2003; Suppl 29:S42–6.
27. Hudson M, Steele R, Lu Y, Thombs BD, Panopalis P, Baron M. Clinical correlates of self-reported physical health status in systemic sclerosis. J Rheumatol 2009;36:1226–9.
28. Hudson M, Impens A, Baron M, Seibold JR, Thombs BD, Walker JG, et al. Discordance between patient and physician assessments of disease severity in systemic sclerosis. J Rheumatol 2010;37:2307–12.
29. Au K, Mayes MD, Maranian P, Clements PJ, Khanna D, Steen VD, et al. Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. Arthritis Care Res (Hoboken) 2010;62:1772–8.
30. Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, et al, for the relaxin investigators and the Scleroderma Clinical Trials Consortium.Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009;60:1102–11.
31. Steen VD. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg 1998;17:48–54.
32. Khanna D, Tsevat J. Health-related quality of life: an introduction [review].Am J Manag Care 2007;9:S218–23.
33. Gladue H, Furst DE, Berrocal V, Seibold JR, Merkel PA, Mayes MD, et al. Comparison of baseline characteristics of the Combined Response Index for Systemic Sclerosis (CRISS) cohort to patients enrolled in clinical trials of diffuse systemic sclerosis [abstract].Arthritis Rheum 2012;64:1464.